Monoclonal Antibodies Against The Rgm A Protein For Use In The Treatment Of Retinal Nerve Fiber Layer Degeneration

Patent No. EP2510001 (titled "Monoclonal Antibodies Against The Rgm A Protein For Use In The Treatment Of Retinal Nerve Fiber Layer Degeneration") was filed by Abbott on Dec 8, 2010. The application was issued on Dec 2, 2015.

Patent Summary

Patent Family

Patent family tree
Statuses, jurisdictions and citation links are shared on request.

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
MITSUBISHI TANABE PHARMASep 1, 2016HOFFMANN EITLE

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

EP2510001

ABBOTT
Application Number
EP10794938A
Filing Date
Dec 8, 2010
Status
Opposition Rejected
Jul 29, 2022
Publication Date
Dec 2, 2015